The Patent Finder

Elbion AG

Also on record
Records under this name other than patents Elbion AG holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to Elbion AG

PatentTitleStatus Expires Confidence
US RE38,624Hydroxyindoles, their use as inhibitors of phosphodiesterase 4 and process for their preparation
Term ended
Term ended Apr 28, 2019 · From the USPTO record
Term endedTerm ended Apr 28, 2019From the USPTO record
US 7,419,9877-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them
Formerly held
Lapsed on the fee record
Ended Sep 2, 2016 · From the USPTO record
Lapsed on the fee recordEnded Sep 2, 2016From the USPTO record
US 7,947,7057-azaindoles and the use thereof as therapeutic agents
Formerly held
Lapsed on the fee record
Ended May 24, 2015 · From the USPTO record
Lapsed on the fee recordEnded May 24, 2015From the USPTO record
US 7,211,5837-azaindoles and the use thereof as therapeutic agents
Formerly held
Lapsed on the fee record
Ended May 1, 2015 · From the USPTO record
Lapsed on the fee recordEnded May 1, 2015From the USPTO record
US 7,169,7877-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same
Formerly held
Lapsed on the fee record
Ended Jan 30, 2015 · From the USPTO record
Lapsed on the fee recordEnded Jan 30, 2015From the USPTO record
US 7,875,618Substituted imidazo[1,5-a]quinoxalines useful as inhibitors of phosphodiesterase 10 for the treatment of neurological and other disorders
Lapsed on the fee record
Ended Jan 25, 2015 · From the USPTO record
Lapsed on the fee recordEnded Jan 25, 2015From the USPTO record
US 7,683,0747-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them
Formerly held
Lapsed on the fee record
Ended Mar 23, 2014 · From the USPTO record
Lapsed on the fee recordEnded Mar 23, 2014From the USPTO record
US 7,550,465Pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
Lapsed on the fee record
Ended Jun 23, 2013 · From the USPTO record
Lapsed on the fee recordEnded Jun 23, 2013From the USPTO record
US 7,309,713Use of the non-opiate analgesic drug flupirtine for the treatment of overactive bladder and associated diseases including urge incontinence, urinary flow problems as a result of prostate hyperplasia and irritable bowel syndrome
Formerly held
Lapsed on the fee record
Ended Dec 18, 2011 · From the USPTO record
Lapsed on the fee recordEnded Dec 18, 2011From the USPTO record
US 6,613,794Hydroxyindoles, their use as inhibitors of phosphodiesterase 4 and processes for their preparation
Lapsed on the fee record
Ended Sep 2, 2011 · From the USPTO record
Lapsed on the fee recordEnded Sep 2, 2011From the USPTO record
10 of 23 patents shown.
Pro members see all 23.
Pro members: see all 23 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited